FY2025 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By William Blair

Sage Therapeutics, Inc. (NASDAQ:SAGE) – William Blair issued their FY2025 earnings per share (EPS) estimates for Sage Therapeutics in a research report issued to clients and investors on Thursday, April 25th. William Blair analyst T. Lugo expects that the biopharmaceutical company will post earnings per share of ($7.01) for the year. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.30) per share.

SAGE has been the topic of several other reports. Truist Financial cut their target price on Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating on the stock in a report on Friday. Royal Bank of Canada cut their target price on Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating on the stock in a report on Friday. Mizuho cut their target price on Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday. HC Wainwright cut their target price on Sage Therapeutics from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday. Finally, The Goldman Sachs Group cut their target price on Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $37.72.

Sage Therapeutics Price Performance

NASDAQ SAGE opened at $13.69 on Friday. Sage Therapeutics has a fifty-two week low of $10.92 and a fifty-two week high of $59.99. The stock’s 50-day moving average is $18.56 and its two-hundred day moving average is $20.64. The firm has a market cap of $822.91 million, a P/E ratio of -1.51 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the prior year, the business posted ($2.46) earnings per share. Sage Therapeutics’s revenue was up 139.4% on a year-over-year basis.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in Sage Therapeutics by 274.2% during the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 883 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Sage Therapeutics by 17.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 1,375 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Sage Therapeutics during the third quarter worth about $219,000. Finally, Quest Partners LLC acquired a new stake in Sage Therapeutics during the fourth quarter worth about $261,000. 99.22% of the stock is owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.